A short selection of developments and evidence clarified during our monthly review. Each highlight explains what it could mean for readers and links to the underlying source.
Latest editorial check: . The digest includes earlier studies and decisions revisited during review. Their original dates are shown below. It is a curated selection, not a complete news service or a claim that every statement on the site has been fully verified.
7 highlights shown. Filters are included in the page URL.
2026-09 digest · Research
A phase 3 trial is testing baricitinib after diagnosis
The September registry update lists BARICADE-PRESERVE as recruiting. This phase 3 trial plans to enrol 300 participants aged 1–35 with newly diagnosed type 1 diabetes; its eligibility criteria include starting the intervention within 100 days of diagnosis.
Why it matters
Our September review brings this larger confirmatory programme into the recruitment picture. It tests whether baricitinib can preserve remaining insulin-producing function after diagnosis.
What remains uncertain
No results are posted. Recruitment was already underway before September: 4 September is the record-update date, not a new-trial launch. Enrolment and July 2028 primary completion are estimates; each site and the study team must confirm eligibility and availability.
CamDiab announced the commercial launch of the CamAPS Liberty feature in Germany, Austria, Switzerland and Luxembourg. It is designed to remove routine meal and snack boluses.
Why it matters
For some readers, fewer meal calculations may matter as much as small differences in glucose outcomes. This is a change in practical availability.
What remains uncertain
A manufacturer launch announcement is not a head-to-head trial. Local rollout, compatible equipment and the individual indication still need checking; this is not worldwide access.
Added to our index in September: results posted on 31 August show that the later phase 2 ladarixin trial did not establish a six-month C-peptide benefit. The study is marked terminated for protocol-defined futility.
Why it matters
Negative results help readers distinguish an interesting immune pathway from a treatment with demonstrated benefit. They also prevent older exploratory findings from becoming the whole story.
What remains uncertain
The primary analysis included 140 participants, not the broader 289-person registry enrolment total. The reported treatment difference was not statistically significant. This does not prove that every related approach will fail; the August posting date is not the date the study stopped.
Our September review separates Omnipod 6’s type 1 results from a different fully closed-loop type 2 programme. Insulet’s June STRIVE announcement reported time in range of 77% versus 73% in the 33 participants with type 1 diabetes aged 14–70.
Why it matters
This was a direct crossover comparison with Omnipod 5, rather than a comparison of unrelated studies. It is a useful early signal about glucose outcomes in this specific group.
What remains uncertain
The comparison used four weeks per system and different targets: 100 mg/dL for Omnipod 6 versus 110 for Omnipod 5. It does not isolate the algorithm from the target setting. Enhanced Omnipod 5 also offers a 100 mg/dL target with compatible Pods and updated software. The lower-bolus findings came from a subsequent phase in which everyone used Omnipod 6, not the randomised crossover. These manufacturer-reported results do not establish long-term safety or a type 1 fully closed-loop product. The announcement describes Omnipod 6 as investigational. This is June evidence clarified in September.
This September digest revisits the May registration decision: Australia approved teplizumab to delay progression to stage 3 in people aged 8 years and older with stage 2 type 1 diabetes.
Why it matters
The country, stage and age matter. An approval elsewhere or for another group does not establish eligibility here.
What remains uncertain
The decision summary does not establish current stock, personal eligibility or subsidised access. Treatment has risks and requires specialist assessment. This was not a September approval.
Rechecked for this digest: the 2025 report found 10 of 12 full-dose participants were not using external insulin at day 365. All participants received immunosuppressive treatment.
Why it matters
This is evidence that transplanted stem-cell-derived islets can provide substantial insulin production in a selected group. It is more informative than a headline that simply says “cure”.
What remains uncertain
The small, uncontrolled study used interim analyses that were not prespecified. Serious adverse events and two deaths were reported across the study. Long-term durability and the balance of benefit and harm need further study; this is not a new September result.
Our September trial review clarified that the main published insulin-aspart/lispro comparison randomised 326 participants. A broader registry total is not the denominator for that comparison.
Why it matters
A result should be paired with the actual participants, treatment and follow-up in its paper. That helps avoid overstating the size of the evidence.
What remains uncertain
The comparison lasted 13 weeks and included different usual-care approaches. It does not establish superiority over every current AID system. The study itself was published in 2022.